Statistical Practices of Safety Monitoring: An Industry Survey
- PMID: 29991276
- DOI: 10.1177/2168479018779973
Statistical Practices of Safety Monitoring: An Industry Survey
Abstract
The Biopharmaceutical Section of the American Statistical Association (ASA) formed a Safety Monitoring Working Group to strengthen collaborations between biostatisticians and safety scientists. The task began by surveying current needs and practices regarding available statistical safety tools and methods, regulatory guidance, and processes needed to support their implementation. The goal is for biostatisticians to become fully engaged safety team members by having the necessary safety skill set including appropriate methodology, regulatory guidance and access to appropriate tools. In this publication, we will discuss our survey results that reveal current practices at 22 pharmaceutical companies and demonstrate how the survey instrument can be used to map an action plan for meeting the demand for improved quantitative safety monitoring.
Keywords: biostatistician; interviews; regulatory guidance; safety monitoring; survey.
Similar articles
-
Recommendations for data monitoring committees from the Clinical Trials Transformation Initiative.Clin Trials. 2017 Aug;14(4):342-348. doi: 10.1177/1740774517707743. Epub 2017 May 13. Clin Trials. 2017. PMID: 28503947 Free PMC article.
-
Understanding the functions and operations of data monitoring committees: Survey and focus group findings.Clin Trials. 2017 Feb;14(1):59-66. doi: 10.1177/1740774516679665. Epub 2016 Nov 24. Clin Trials. 2017. PMID: 27885056
-
American Society of Clinical Oncology policy statement: oversight of clinical research.J Clin Oncol. 2003 Jun 15;21(12):2377-86. doi: 10.1200/JCO.2003.04.026. Epub 2003 Apr 29. J Clin Oncol. 2003. PMID: 12721281
-
Issues in regulatory guidelines for data monitoring committees.Clin Trials. 2004;1(2):162-9. doi: 10.1191/1740774504cn019xx. Clin Trials. 2004. PMID: 16281888 Review.
-
Data monitoring and interim analyses in the pharmaceutical industry: ethical and logistical considerations.Stat Med. 1993 Mar;12(5-6):471-9. doi: 10.1002/sim.4780120512. Stat Med. 1993. PMID: 8493425 Review.
Cited by
-
Comparison of statistical methods for the analysis of recurrent adverse events in the presence of non-proportional hazards and unobserved heterogeneity: a simulation study.BMC Med Res Methodol. 2022 Jan 20;22(1):24. doi: 10.1186/s12874-021-01475-8. BMC Med Res Methodol. 2022. PMID: 35057743 Free PMC article. Clinical Trial.
-
Visualising harms in publications of randomised controlled trials: consensus and recommendations.BMJ. 2022 May 16;377:e068983. doi: 10.1136/bmj-2021-068983. BMJ. 2022. PMID: 35577357 Free PMC article.
-
Understanding current practice, identifying barriers and exploring priorities for adverse event analysis in randomised controlled trials: an online, cross-sectional survey of statisticians from academia and industry.BMJ Open. 2020 Jun 11;10(6):e036875. doi: 10.1136/bmjopen-2020-036875. BMJ Open. 2020. PMID: 32532777 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical